Worth Watching: Ironwood Pharmaceuticals, Inc. Stock Is Rising Now

Worth Watching: Ironwood Pharmaceuticals, Inc. Stock Is Rising Now

The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is a huge mover today! The stock increased 3.77% or $0.6 on November 23, hitting $16.53. About 1.77M shares traded hands or 14.94% up from the average. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has risen 52.49% since April 22, 2016 and is uptrending. It has outperformed by 47.08% the S&P500.
The move comes after 9 months positive chart setup for the $2.35 billion company. It was reported on Nov, 24 by Barchart.com. We have $17.69 PT which if reached, will make NASDAQ:IRWD worth $164.50M more.

Analysts await Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to report earnings on February, 16. They expect $-0.24 EPS, down 140.00% or $0.14 from last year’s $-0.1 per share. After $-0.18 actual EPS reported by Ironwood Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 33.33% negative EPS growth.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Ratings Coverage

Out of 10 analysts covering Ironwood Pharmaceuticals (NASDAQ:IRWD), 4 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 40% are positive. $24 is the highest target while $8 is the lowest. The $13.67 average target is -17.30% below today’s ($16.53) stock price. Ironwood Pharmaceuticals has been the topic of 19 analyst reports since August 6, 2015 according to StockzIntelligence Inc. WallachBeth Capital maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Tuesday, September 27 with “Hold” rating. Wedbush maintained the shares of IRWD in a report on Thursday, April 28 with “Neutral” rating. The rating was initiated by Goldman Sachs on Monday, March 21 with “Neutral”. On Friday, February 19 the stock rating was maintained by Wedbush with “Neutral”. Wedbush maintained it with “Neutral” rating and $13 target price in Monday, October 24 report. Cowen & Co upgraded the shares of IRWD in a report on Wednesday, April 6 to “Outperform” rating. As per Tuesday, May 10, the company rating was maintained by Mizuho. Barclays Capital maintained the stock with “Equal-Weight” rating in Friday, February 19 report. The company was maintained on Friday, November 4 by Mizuho. BTIG Research initiated it with “Buy” rating and $15 target price in Friday, December 11 report.

According to Zacks Investment Research, “Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company that discovers, develops, and intends to commercialize innovative human medicines. The Company’s first in class compound, Linaclotide, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation and chronic constipation. The Company also focuses on one Phase 1 pain drug candidate and multiple preclinical programs, as well as on building a specialty biochemicals business based on a proprietary strain-development platform. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is headquartered in Cambridge, Massachusetts.”

Insitutional Activity: The institutional sentiment decreased to 1.4 in Q2 2016. Its down 0.20, from 1.6 in 2016Q1. The ratio fall, as 13 funds sold all Ironwood Pharmaceuticals, Inc. shares owned while 34 reduced positions. 22 funds bought stakes while 53 increased positions. They now own 136.24 million shares or 2.82% less from 140.19 million shares in 2016Q1.
Geode Lc has 954,033 shares for 0.01% of their US portfolio. Schwab Charles Mgmt holds 435,942 shares or 0.01% of its portfolio. Sector Gamma As accumulated 1.77M shares or 4.68% of the stock. The New York-based Amer International Group has invested 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Teachers Advsr owns 221,344 shares or 0.01% of their US portfolio. Capwealth Advsr Limited Company last reported 7,400 shares in the company. Amalgamated Bancshares accumulated 13,668 shares or 0.01% of the stock. Broderick Brian C has invested 0.85% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). The New York-based Consonance Capital Mngmt Limited Partnership has invested 9.12% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Bridger Management Limited Liability Com owns 5.92M shares or 5% of their US portfolio. Mirae Asset Invs Limited holds 0.02% or 55,259 shares in its portfolio. Citadel Llc last reported 10,194 shares in the company. First Tru Advsr Lp holds 38,034 shares or 0% of its portfolio. Tudor Investment Et Al holds 0.01% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 34,118 shares. Manufacturers Life Communication The holds 0% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 89,167 shares.

Insider Transactions: Since May 25, 2016, the stock had 0 insider buys, and 4 insider sales for $309,631 net activity. OLANOFF LAWRENCE S sold $43,904 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Tuesday, September 6. Gilbert Halley E sold $247,152 worth of stock. $2,803 worth of shares were sold by Consylman Gina on Friday, August 19.

IRWD Company Profile

Ironwood Pharmaceuticals, Inc., incorporated on January 5, 1998, is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Firm operates through human therapeutics segment. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. The Company’s product, linaclotide, which is available in the United States under the brand name LINZESS, and is available in European countries under the brand name CONSTELLA. The Firm in collaboration with Astellas Pharma Inc. (Astellas) is engaged in advancing linaclotide colonic release, a second-generation product candidate with the potential to improve abdominal pain relief in adult IBS-C patients, as well as in patients with additional GI, disorders where lower abdominal pain is a predominant symptom, such as IBS-mixed (IBS-M), ulcerative colitis and diverticulitis. In addition, the Company is engaged in developing therapeutic platforms for the treatment of vascular and fibrotic diseases, and refractory gastroesophageal reflux disease (GERD).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment